ArticleBMC microbiology2025
Co-resistance and plasmid-mediated co-dissemination of florfenicol and azithromycin resistance in non-O157 Shiga toxin-producing Escherichia coli from cattle in Xinjiang, China.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Triple-layered nanogel for targeted and sustained delivery of florfenicol against bacterial enteritis.International journal of pharmaceutics: X · 2026Article
- Article
- Virulence Traits and Drug Resistance of STEC Isolated from Layer Poultry andMicroorganisms · 2026Article
- Hidden carriers: multidrug-resistant bacteria in hedgehogs from a wildlife rescue centre.Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFlorfenicol is a critical antibiotic used in cattle to manage respiratory infections, while azithromycin is recommended for treating early-stage Shiga toxin-producing Escherichia coli (STEC) infections. This study focused on examining the co-resistance and mechanisms of co-dissemination of resistance to florfenicol and azithromycin in 367 non-O157 STEC strains isolated from cattle in Xinjiang between 2015 and 2023.
resultsAmong these isolates, 16.3% showed resistance, with drug resistance rates ranging from 5.4 to 10.6% for tetracycline, ampicillin, cefotaxime, streptomycin, sulfamethoxazole, florfenicol, aztreonam, azithromycin, gentamicin, ceftazidime, and piperacillin. Resistance to cefepime, ampicillin-sulbactam, amikacin, amoxicillin-clavulanic acid, levofloxacin, ciprofloxacin, and piperacillin-tazobactam was lower, varying from 0.3 to 3.5%. Notably, 9.0% (n = 33) isolates exhibited multiple drug resistance, while 8.4% (n = 31) were resistant to florfenicol and/or azithromycin. Conjugation experiments demonstrated that resistance genes floR and/or mph(A) were transferred to the recipient strain Escherichia coli J53, leading to phenotypic resistance to florfenicol and/or azithromycin in the transconjugants. Whole genome sequencing (WGS) of STEC W24 identified that floR and mph(A) were located on a 77,016 bp IncA/C type plasmid, designated as W24-floR-mph(A). A genetic structure with three IS26 and one IS6100 sequences flanking the multi-drug resistance region was detected, including two IS26 copies adjacent to floR, tet(A), aph(6)-Id_1, aph(3'')-Ib_5, sul2 and mph(A).
conclusionsThe findings highlight the presence of florfenicol and azithromycin resistance in bovine non-O157 STEC in Xinjiang, with floR and mph(A) genes residing on plasmids capable of horizontal transfer. Plasmids, transposons, and insertion sequences may mediate the dissemination of antimicrobial resistance genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.